Alzheimer's Disease & Dementia
Findings among individuals with a genetic mutation known to cause Alzheimer's.
Alzheimer's disease and related dementias burden is expected to increase to 3.3% in 2060.
Three factors help identify absolute 10-year risk of Alzheimer's disease, all dementia for different groups.
Disruption of molecular, genetic, clinical networks by human herpesvirus in brains of subjects with AD.
As the neurodegenerative processes of Alzheimer disease and Parkinson disease are different, early cognitive impairment also present differently in these diseases.
Currently, there are no US consensus on best clinical practice guidelines that incorporate multispecialty recommendations for evaluating cognitive impairment that are thought to be due to Alzheimer's disease and Related Dementias (ADRD) for use by physicians and nurse practitioners.
Thinning of the retinal nerve fiber layer has been linked to worsening cognitive function and may be valuable in identifying individuals who may be at risk for cognitive decline.
In patients with and without dementia, amyloid-positive and negative results were significantly linked to diagnoses and treatment changes.
The genetic risk score primarily modified the risk for and onset of dementia and AD among homozygous carriers for APOE ε4.
Lower BCAA levels may be associated with an increased risk of incident dementia.
Elderly individuals without dementia who have elevated daytime sleepiness may be at greater risk for β-amyloid accumulation.
The independent data monitoring committee (IDMC) concluded that the 2 trials (AMARANTH and DAYBREAK-ALZ) investigating the treatment in mild Alzheimer's disease dementia, were not likely to meet their primary endpoints of change from baseline on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale.
Brain autopsies of participants of the Rush Memory Aging project (n=428) were studied to identify the association between brain pathologies and total daily physical activity and mortality.
The NIA-AA has proposed updates to the 2011 guidelines for symptomatic stages of Alzheimer's disease to include the idea that certain imaging and cerebrospinal fluid biomarkers are valid proxies for neuropathologic changes of AD.
Short-term proton pump inhibitors (PPIs) are linked to an elevated risk for hip fracture among patients with Alzheimer's disease. No link is seem among patients taking long-term or cumulative PPIs.
In patients with mild Alzheimer's disease solanezumab, an antibody designed to facilitate clearance of amyloid-beta plaques, did not significantly reduce cognitive decline over time.
Attaining higher education may aid in the prevention of Alzheimer's disease.
Over 6 million Americans were diagnosed with Alzheimer's this year, which will increase to 15 million by 2060.
Obstructive sleep apnea and sleep-disordered breathing are associated with amyloid deposition.
Approximately 11% of dementia cases for people living within 164 feet of a major roadway might be attributed to this proximity to traffic.
Depending on race, sex, and ethnicity, the right statin type may lower the risk of Alzheimer disease.
A recent cohort study evaluated the risk of developing Alzheimer dementia after ADT in 16,888 men with prostate cancer, 14.2% of whom were treated with ADT.
Facing dementia with strength and courage can inspire and comfort patients' families.
Patients administered low doses of benzodiazepines have an elevated risk of dementia and Alzheimer's disease compared with patients who received higher doses.
Patients treated with androgen deprivation therapy had a 1.88-times increased rate of developing Alzheimer's disease.
Research reveals that focus on diet, mental health, and lifestyle may help lower the number of new cases of Alzheimer's disease.
The MIND diet combines the Mediterranean diet with the DASH diet, both of which call for high consumption of fruits, vegetables, and fish.
Patients who ran more than 15.3 miles per week had a 40% reduced risk of dying from Alzheimer disease.
Researchers have identified 10 proteins in the blood that may be predictors of Alzheimer disease.
A pilot study reports deep brain stimulation targeted at the nucleus basalis of Meynert improved or stabilized memory in Alzheimer's patients.